A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND FOOD EFFECT OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERS
Phase 1
Recruiting
- Conditions
- upus erythematosusMedDRA version: 21.1Level: LLTClassification code: 10025139Term: Lupus erythematosus systemic Class: 10028395Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2023-507504-31-00
- Lead Sponsor
- Ventus Therapeutics U.S. Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method